Navigation Links
Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
Date:7/29/2008

SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company") (Nasdaq: CTIC; MTA) today announced that it has entered into an equity line of credit agreement with Midsummer Investment, Ltd. for the sale of up to $12 million of common stock over time (the "Agreement"). The stock would be issued upon exercise of a warrant pursuant to the terms of the Agreement.

The Company has the right to raise cash under the Agreement for shares of the Company's common stock on a periodic basis. The number and price per share of each issuance are determined by a contractual formula based on the trading volume and a discount to the volume weighted average price of the Company's common stock, as reported by the Milan Stock Exchange, over a preceding period of trading days.

The first draw under the Agreement is expected to take place in August 2008, and the Agreement contemplates that additional draws (subject to customary closing conditions) will occur until the warrant is exercised in full or the Company elects to suspend future closings under the Agreement. The Company can choose to reactivate the line of credit following any such suspension.

A prospectus supplement relating to the common stock to be issued in respect of the Agreement was filed with Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
2. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
3. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
4. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
6. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
7. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
8. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
9. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
10. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
11. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 A new study published ... may contribute to the development of colorectal cancer in ... The study was authored by Alberto Martin of the ... cause intestinal cells to multiply and create tumors in ... , “What’s interesting about this study,” said Shahab ...
(Date:8/1/2014)... Canadian, OK (PRWEB) August 01, 2014 ... graduate from the program at the drug rehab center ... in the year 2001, Narconon Arrowhead is the flagship ... come from across the United States for services there. ... the center has recent outcome studies as well as ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... recently announced the addition of a comprehensive report ... titled ‘Infusion System Market (Large Volume, Disposable, Syringe, ... Share, Growth, Trends And Forecast, 2013 – 2019’ ... website http://www.transparencymarketresearch.com . , To begin with, ...
(Date:8/1/2014)... HealthDay Reporter , THURDAY, July ... healthier than school cafeteria fare, a new study suggests. ... lunches third and fourth graders brought from home met three ... "Our findings are similar to results of other studies of ... that high-calorie packaged foods and beverages are more common than ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although older women ... make asthma care a priority, according to a new study. ... from asthma much more than men over 65," concluded Dr. ... of Allergy, Asthma and Immunology (ACAAI), in an organization news ... age 65 years and older is nearly four times higher ...
Breaking Medicine News(10 mins):Health News:Carbs May Contribute to Colon Cancer 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3Health News:Older Women With Asthma Face Worse Health Outcomes 2
... April 22 Aida,Pharmaceuticals, Inc. (OTC Bulletin ... investor-focused corporate synopsis on its English,language website, ... as a,pdf document. The synopsis details Aida ... line, the drugs in its,development pipeline, as ...
... leads to adverse reactions identified, officials add , , MONDAY, ... now been found in at least 10 countries, not ... to ensure the safety of the blood thinner, U.S. ... contaminated lots of the blood thinner have been traced ...
... Available in Smaller Package for Healthy Snacking, MINDEN, ... the maker of the award-winning Detour(R) bar, today announced,the ... their top,selling Detour Caramel Peanut Bar(TM). The snack size ... choice for energy seekers living a,healthy lifestyle. With seven ...
... The American College of Allergy,Asthma & Immunology ... surveys that highlight the importance of improving care ... and other important,information for physicians and patients are ... like Sepracor who are,committed to driving the dialogue ...
... SAN JUAN, Puerto Rico, April 22 Triple-S,Management Corporation ... plans,to release financial results for the first quarter ended ... 2008. Ramon M. Ruiz-Comas, President and,Chief Executive Officer, and ... host a conference call to discuss these,results and the ...
... Formation Capital, LLC is,pleased to announce that ... joined the company as Senior Executive Vice President ... be leading the day-to-day,operations and direction of the ... leading change, building shareholder value, and managing Board,and ...
Cached Medicine News:Health News:Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website 2Health News:FDA: Contaminated Heparin Found in 11 Countries 2Health News:FDA: Contaminated Heparin Found in 11 Countries 3Health News:FDA: Contaminated Heparin Found in 11 Countries 4Health News:Detour(R) Unveils Snack Size Protein Bar 2Health News:Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast 2Health News:Damian Dell'Anno Joins Formation Capital as Chief Operating Officer 2
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, ... an update on its pipeline and new product ... expects to initiate a Phase 2a study of ... developed for the management of patients with acute ... Staccato -based product candidates for development - ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
S.O.C. Medium...
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: